Abstract
In the present study, the effect of cucurbitacin B and cerulenin combination on osteosarcoma was investigated to develop an effective treatment regimen. The IC50 values of cerulenin and cucurbitacin B combination in the proportion of 1:1, 1:2 and 2:1 were 3.5, 7.2 and 8.6 mu g/mL, respectively. The combination index (CI) values of < 0.95 for inhibition of growth and < 0.93 for inhibition of SENP5 expression clearly indicated synergism between the two. The Q-value for combination of 1 mu g/mL cerulenin and 1 mu g/mL cucurbitacin B was 1.2. AI calculated for tumor tissues treated with a combination of cucurbitacin B and cerulenin (26.2 +/- 8.4%) was higher than that of the tissues treated separately with cucurbitacin B (14.5 +/- 6.8%) or cerulenin (12.6 +/- 7.5%). The AI for untreated tumor tissues was 4.2 +/- 1.5%. Thus, the combination of cucurbitacin B and cerulenin can be a promising regimen in the treatment of osteosarcoma.
| Original language | English |
|---|---|
| Pages (from-to) | 956-961 |
| Number of pages | 6 |
| Journal | Bangladesh Journal of Pharmacology |
| Volume | 10 |
| Issue number | 4 |
| DOIs | |
| State | Published - Jan 2015 |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Keywords
- cerulenin
- cucurbitacin B
- epirubicin
- peptidase
- protein SENP5
- terpenoid
- unclassified drug
- antineoplastic activity
- apoptosis
- Article
- cancer combination chemotherapy
- cancer inhibition
- controlled study
- drug potentiation
- human
- human cell
- human tissue
- IC50
- in vitro study
- in vivo study
- monotherapy
- osteoblast
- osteosarcoma
- osteosarcoma cell line
- protein expression
- Cerulenin
- Cucurbitacin B
- Osteosarcoma
- Tumor
Indexed by
- SCIE
- Scopus
Fingerprint
Dive into the research topics of 'Enhanced antitumor activity of cucurbitacin B combined with cerulenin in osteosarcoma'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver